220 related articles for article (PubMed ID: 12962025)
1. [Interferon beta treatment in multiple sclerosis].
Ochi H
Nihon Rinsho; 2003 Aug; 61(8):1367-73. PubMed ID: 12962025
[TBL] [Abstract][Full Text] [Related]
2. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
Cook SD
J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta and multiple sclerosis: look at the evidence.
Patti F; Reggio A
Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
5. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
6. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
7. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.
Bayas A; Gold R
J Neurol; 2003 Dec; 250 Suppl 4():IV3-8. PubMed ID: 14712395
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
9. [Recent therapeutic strategy for multiple sclerosis].
Itoyama Y
Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
[TBL] [Abstract][Full Text] [Related]
10. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
Correale J; Cristiano E
Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying therapy in multiple sclerosis: update and clinical implications.
Goodin DS
Neurology; 2008 Dec; 71(24 Suppl 3):S8-13. PubMed ID: 19064873
[TBL] [Abstract][Full Text] [Related]
12. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
14. [Beta interferon in multiple sclerosis: pharmacological differences].
Allain H; Bentué-Ferrer D; Schück S; Ruffault A
Rev Neurol (Paris); 1999; 155 Suppl 2():S24-30. PubMed ID: 10367322
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate (Copaxone).
Francis DA
Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
Cristiano E
Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
[TBL] [Abstract][Full Text] [Related]
17. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
Comi G
Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
[TBL] [Abstract][Full Text] [Related]
18. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
19. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
Durelli L
J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
[TBL] [Abstract][Full Text] [Related]
20. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
Stone LA; Frank JA; Albert PS; Bash C; Smith ME; Maloni H; McFarland HF
Ann Neurol; 1995 May; 37(5):611-9. PubMed ID: 7755356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
